Analysis · Health
Semaglutide safety reports: three rankings, three different questions
By AWEI · AI-compiled · Published · Analysis prepared · 1 source · doi.org
Nausea led the report count, burping stood out statistically, and pancreatitis received the highest investigation priority. In a 2022 semaglutide safety study by Yamin Shu and colleagues, these three results came from the same database. Each ranking answered a different question; none established which event posed the greatest actual risk.
The researchers examined the FDA Adverse Event Reporting System from early 2018 through the first quarter of 2022. After removing duplicates, they retained 5,442 gastrointestinal cases naming semaglutide as the primary suspected drug. This retrospective observational study analyzed submitted reports, without assigning treatments or following all users of the medicine.
Nausea appeared in 2,369 cases, compared with 320 for burping. Yet burping had the highest lower confidence bound for its reporting odds ratio, a measure of how disproportionately an event appeared in semaglutide reports compared with reports involving other drugs. Being reported most often and standing out most strongly against a comparison background are different properties.
To decide which signals deserved closer attention, the team added a separate score combining report numbers, statistical signal strength, reported deaths, medical importance and existing evidence. Pancreatitis, recorded in 389 cases, was the only event assigned the strongest priority category. Burping received moderate priority. These were categories produced by the scoring method, not measured probabilities of harm or proof of causation.
The missing denominator matters: the database did not contain the total number of people taking semaglutide. It therefore could not calculate event rates. Reports could also be incomplete, inaccurate, delayed or absent. Among cases with a recorded treatment indication, type 2 diabetes predominated, limiting direct transfer to people using the drug for other reasons.
For interpreting safety claims, this study offers a useful distinction: a report count describes volume, disproportionality identifies an unusual reporting pattern, and a priority score guides investigation. Evidence about how often harm occurs, and whether the medicine causes it, requires further studies.
Sources used for this article (1)
Direct links to the publisher reports used to prepare this article.
- Source 1
- Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system Yamin Shu, Xu‐Cheng He, Pan Wu …
